H.C. Wainwright analyst Amit Dayal maintained a Buy rating on Cibus on August 15 and set a price target of $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amit Dayal has given his Buy rating due to a combination of factors that highlight Cibus’s strategic positioning and potential for growth. The company’s recent cost-cutting and streamlining initiatives are expected to positively impact its financials starting from the third quarter of 2025. This strategic focus on optimizing their Trait Machine gene editing processes, particularly for weed management traits in rice, and advancing customer-funded sustainable ingredients programs, positions Cibus well for future commercial success.
Additionally, regulatory advancements, such as the USDA’s designation of Cibus’s HT2 herbicide-tolerance trait in canola as not regulated, and similar developments in Ecuador for rice traits, open up new market opportunities in North and Latin America. The potential partnership with a Consumer-Packaged Goods producer for biofragrance products could also lead to significant royalty revenues. These factors, combined with the company’s efforts to expand relationships with rice seed companies, contribute to the positive outlook and justify the Buy rating.